What is Xeltis?
Xeltis is at the forefront of developing advanced polymer-based restorative devices designed for cardiovascular applications, including heart valves and small-diameter blood vessels for coronary artery bypass graft (CABG) surgery and hemodialysis vascular access. Originating from the merger of two Dutch and Swiss university spin-offs, Xeltis operates across The Netherlands and the USA. The company's technology is currently investigational and not yet approved for sale. The recent substantial capital infusion, following earlier rounds such as Series B, C, and D, positions Xeltis for accelerated development and potential commercialization of its groundbreaking medical solutions.
How much funding has Xeltis raised?
Xeltis has raised a total of $90.1M across 3 funding rounds:
Series B
$3.3M
Series C
$52.8M
Series D
$34M
Series B (2015): $3.3M with participation from Kurma Partners, Life Sciences Partners, and VI Partners
Series C (2017): $52.8M led by Life Sciences Partners, Kurma Partners, VI Partners, and Ysios Capital
Series D (2023): $34M supported by EQT Life Sciences, Invest-NL, and Grand Pharmaceutical Group
Key Investors in Xeltis
Kurma Partners
Kurma Partners is a venture capital firm specializing in healthcare and biotechnology, with a focus on transforming scientific discoveries into advanced medical solutions for severe diseases. They invest across various maturity stages, supporting companies with high unmet medical needs.
Life Sciences Partners
Life Sciences Partners (LSP) is a European venture capital firm dedicated to investing in the life sciences sector. They focus on companies developing innovative therapies and technologies to address significant unmet medical needs, contributing to the advancement of healthcare.
VI Partners
VI Partners is a Swiss venture capital firm with over 20 years of experience supporting innovative Healthcare and Technology companies. They have a strong track record of investing in ventures that drive technological advancements in the health sector.
What's next for Xeltis?
The substantial enterprise-level funding, particularly the recent major strategic investment, signals a critical growth phase for Xeltis. This capital is expected to fuel further clinical trials, regulatory submissions, and the scaling of manufacturing capabilities. The backing from prominent life sciences investors suggests a strategic focus on advancing Xeltis's pipeline towards market approval and broader adoption. The company's trajectory indicates a move towards late-stage development and potential commercialization, aiming to address significant unmet needs in cardiovascular treatment.
See full Xeltis company page
